Edwards Lifesciences Corporation (EW) Income Statement

The sequence of quarterly revenue growth rates, ranging from roughly 6% to 17% over the ten-quarter window, points to a business that has re-accelerated after softer periods rather than decelerating steadily. The latest 10.5% print is below the 13.6% and 16.7% readings of the prior two quarters, which may indicate normalization rather than deterioration, though the data does not isolate volume versus pricing contributions. Investors should monitor whether guidance-supported growth persists once the timing effects in the TMTT ramp are separated from core TAVR demand.

The tight band of gross margins suggests the proprietary valve technology and manufacturing complexity translate into durable unit economics rather than cyclical pricing benefits. The latest 78.5% reading sits below the 2024Q3 peak of 80.6%, which may reflect product mix shifts toward lower-margin TMTT systems or early-stage launch costs. Comparing against peers in the data set, the margin profile is competitive, though it remains below Medtronic and Boston Scientific at the gross line, warranting continued observation of mix trends.

SG&A rose to $560.9M in the latest quarter, consuming a larger share of gross profit than in the prior year, which indicates weakening operating leverage at the margin. The contrast between steady gross profit growth and volatile operating income implies that fixed commercial and clinical support costs are absorbing incremental revenue. Investors should evaluate whether the operating margin decline reflects temporary investment timing or a structural increase in the cost base required to defend TAVR share.